NO20052009D0 - Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom - Google Patents

Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Info

Publication number
NO20052009D0
NO20052009D0 NO20052009A NO20052009A NO20052009D0 NO 20052009 D0 NO20052009 D0 NO 20052009D0 NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 D0 NO20052009 D0 NO 20052009D0
Authority
NO
Norway
Prior art keywords
treatment
combination therapy
myelodysplastic syndrome
acute leukemia
leukemia
Prior art date
Application number
NO20052009A
Other languages
English (en)
Other versions
NO20052009L (no
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20052009D0 publication Critical patent/NO20052009D0/no
Publication of NO20052009L publication Critical patent/NO20052009L/no

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052009A 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom NO20052009L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
NO20052009D0 true NO20052009D0 (no) 2005-04-25
NO20052009L NO20052009L (no) 2005-06-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052009A NO20052009L (no) 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Country Status (10)

Country Link
EP (1) EP1575582A4 (no)
JP (1) JP2006508119A (no)
CN (1) CN1720044A (no)
AU (2) AU2002348178A1 (no)
BR (1) BR0215935A (no)
CA (1) CA2504611A1 (no)
CR (1) CR7804A (no)
MX (1) MXPA05004711A (no)
NO (1) NO20052009L (no)
WO (1) WO2004043461A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
WO2007008479A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
PL2120568T3 (pl) * 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
WO2009075841A2 (en) 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
WO2018234433A1 (en) * 2017-06-22 2018-12-27 Les Laboratoires Servier COMBINATION OF MCL-1 INHIBITOR AND CARE TREATMENT STANDARD FOR HEMATOLOGICAL CANCERS, USES AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
EP3917397A4 (en) * 2019-01-28 2022-10-26 Board of Regents, The University of Texas System COMBINATION METAL CHELATOR THERAPY FOR THE TREATMENT OF CANCER
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
AU2021372482A1 (en) * 2020-10-27 2023-05-25 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
JP3888971B2 (ja) * 2000-08-08 2007-03-07 イムノメディクス， インコーポレイテッド 慢性骨髄性白血病の免疫療法

Also Published As

Publication number Publication date
MXPA05004711A (es) 2005-08-03
CN1720044A (zh) 2006-01-11
EP1575582A4 (en) 2009-03-11
CA2504611A1 (en) 2004-05-27
AU2002348178A1 (en) 2004-06-03
JP2006508119A (ja) 2006-03-09
NO20052009L (no) 2005-06-27
CR7804A (es) 2008-10-29
EP1575582A1 (en) 2005-09-21
AU2010201113A1 (en) 2010-04-15
BR0215935A (pt) 2005-08-09
WO2004043461A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20041975D0 (no) Bicyklisk oksopyridin og oksopyrimidinderivater
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
NO20044272L (no) Legemiddel for behandling og/eller forebyggelse av kronisk avstotning
DE60322507D1 (de) Steuerbarer katheter oder dergleichen
DE60313805D1 (de) Steuerbarer Katheter
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DE60328797D1 (de) Blutbehandlungsgerät
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
IS6918A (is) Meðferð erfiðra æxla með notkun epóþílon afleiða
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20033498D0 (no) Fremgangsmåte for behandling og törking av trevirke
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DE60319400D1 (de) Atemfähiges und mehrlagiges gewebe
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ATE442835T1 (de) Oberflächenbehandlung
NO20040087L (no) Fremgangsmate for behandling av sovnloshet
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
EP1562606A4 (en) METHODS OF USING VITAMIN D COMPOUNDS TO TREAT MYELODYSPLASIC SYNDROMES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application